Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.57 |
| ▸ | KDR | P35968 | 9/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.57 |
| ▸ | FLT1 | P17948 | 6/20 | 0.57 |
| ▸ | FLT4 | P35916 | 6/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822070 | 0.86 | EGFR (0.53) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL30822079 | 0.85 | CYP1A2 (0.47) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL27145372 | 0.82 | EGFR (0.57) | EGFRKDREPHA2 | |
| SCHEMBL30820521 | 0.81 | EGFR (0.61) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL29168736 | 0.81 | EGFR (0.61) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL30820600 | 0.79 | FBP1 (0.62) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL29168723 | 0.79 | FBP1 (0.62) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL30820454 | 0.79 | EGFR (0.59) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL27148399 | 0.79 | EGFR (0.59) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL30820517 | 0.75 | EGFR (0.64) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 24/4885FGFR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.